Achillion Pharmaceuticals (ACHN) : During the past 4 weeks, traders have been relatively bearish on Achillion Pharmaceuticals (ACHN), hence the stock is down -1.25% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.22% relative to the S&P 500. The 4-week change in the price of the stock is -0.23% and the stock has fallen -4.17% in the past 1 week.
The stock has recorded a 20-day Moving Average of 1.03% and the 50-Day Moving Average is 0.02%. Achillion Pharmaceuticals (NASDAQ:ACHN): On Fridays trading session , Opening price of the stock was $8.86 with an intraday high of $8.87. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $8.625. However, the stock managed to close at $8.74, a loss of 1.24% for the day. On the previous day, the stock had closed at $8.85. The total traded volume of the day was 1,098,139 shares.
The company Insiders own 6.52% of Achillion Pharmaceuticals shares according to the proxy statements. Institutional Investors own 81.32% of Achillion Pharmaceuticals shares. Also, Chardan Capital initiates coverage on Achillion Pharmaceuticals (NASDAQ:ACHN). The rating major has initiated the coverage with sell rating on the shares. The Analysts at Chardan Capital announces a current price target of $4 per share. The rating by the firm was issued on July 14, 2016.
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.